Life Sciences Update
H1 2025 was dynamic for the life sciences industry
In this edition of Cushman & Wakefield’s life sciences market report External Link, we explore national trends and provide an in-depth analysis of leading global life sciences markets in this rapidly evolving industry.
AI adoption is revolutionizing drug discovery, boosting efficiency and success rates in clinical trials. However, global uncertainty has slowed leasing activity, with vacancy rates reaching 23.3% across major markets.
In the U.S., R&D capital markets investment sales rose 63% year-over-year, driven by major hub markets. Europe saw a 22% rise in VC funding and a 5% uptick in M&A deal volume. Meanwhile, the Chinese mainland continues to emerge as a global biopharma leader, with rising R&D investment and breakthroughs in therapeutics and MedTech.
Looking ahead, the industry faces challenges such as patent expirations, tariff uncertainties and evolving pricing policies. However, opportunities abound in AI-driven innovation, regionalized supply chains and emerging markets.